Adalimumab can treat secondary sacroiliac arthritis caused by autoimmune diseases such as ankylosing spondylitis, for primary sacroiliac arthritis application of adalimumab is generally ineffective.
Sacroiliac arthritis is divided into primary and secondary types, secondary sacroiliac arthritis is mostly caused by autoimmune diseases, infectious diseases and congenital diseases, adalimumab can treat sacroiliac arthritis caused by autoimmune diseases such as ankylosing spondylitis.
Adalimumab is an anti-inflammatory and anti-rheumatic drug that can treat ankylosing spondylitis and improve stiffness and pain in the joints and limited joint movement. Ankylosing spondylitis is prone to secondary sacroiliac arthritis and the application of this drug is also effective.
Adalimumab is a biotherapeutic drug, and common adverse reactions are infections such as nasopharyngitis, upper respiratory tract infections, and injection site reactions such as erythema, itching, and bleeding, as well as headache and skeletal muscle pain. It should not be used by those who are allergic to adalimumab and is contraindicated during lactation and pregnancy.
Primary sacroiliac arthritis is usually caused by joint degeneration, so the application of adalimumab is not effective. It is recommended that patients with sacroiliac arthritis actively cooperate with the doctor, according to the condition of targeted treatment, the use of medication should be carried out under the guidance of the doctor, and can not be used blindly on their own.